HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

yimitasvir

a hepatitis C virus nonstructural protein 5A (NS5A) inhibitor

Also Known As:

DAG-181; DAG181; yimitasvir phosphate

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- yimitasvir: 2

Experts

1.	Chen, Rui: 1 article (01/2020)
2.	Guan, Xiao-Duo: 1 article (01/2020)
3.	Hu, Pei: 1 article (01/2020)
4.	Luo, Lin: 1 article (01/2020)
5.	Tang, Xian-Ge: 1 article (01/2020)
6.	Wu, Dan: 1 article (01/2020)
7.	Xie, Hong-Ming: 1 article (01/2020)
8.	Zhang, Ying-Jun: 1 article (01/2020)
9.	Chen, Guiling: 1 article (07/2018)
10.	Chen, Hong: 1 article (07/2018)

Related Diseases

1.	Infections 01/01/2020 - "The objective of this analysis was to develop a population pharmacokinetic model of yimitasvir in Chinese healthy volunteers and HCV infection patients. " 07/01/2018 - "Twenty-four patients with chronic HCV genotype 1 infection were randomized to receive a 7-day course of yimitasvir phosphate at daily doses of 30, 100 or 200 mg or placebo. " 01/01/2020 - "Yimitasvir is a novel, oral hepatitis C virus (HCV) non-structural protein 5A inhibitor for the treatment of chronic HCV genotype 1 infection. "
2.	Chronic Hepatitis C 01/01/2020 - "Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients With Chronic Hepatitis C Virus Infection."
3.	Virus Diseases (Viral Diseases) 01/01/2020 - "Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients With Chronic Hepatitis C Virus Infection."

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)